High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)

Jabbour, Elias; Koscielny, Serge; Sebban, Catherine; Peslin, N.; Patte, Catherine; Gargi, Thérèse; Biron, Pierre; Fermé, Christophe; Bourhis, Jean‐Henri; Vantelon, J; Arnaúd, Philippe; Ribrag, Vincent

doi:10.1038/sj.leu.2404156

Cited by 37 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not confirm the poor outcome associated with bone marrow involvement discribed in a recent cohort of 27 patients. 26 The observation that a small subset of patients who responded slowly after induction and required a second chemotherapy course to achieve CR had better OS remains to be clarified but is in agreement with the observation by Thomas et al. that a slow response to induction chemotherapy did not have a poor prognistic significance.…”

Section: Discussionsupporting

confidence: 74%

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

Hunault

Truchan-Graczyk²,

Caillot³

et al. 2007

Haematologica

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 74%

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

Hunault

Truchan-Graczyk²,

Caillot³

et al. 2007

Haematologica

View full text Add to dashboard Cite

“…LL is rare in adult patients, the most recent prospective series dealing with 27-34 total patients (a figure comparable to our study), with only a single study from Germany including exceptionally 45 patients [8,9,19,20]. In the NILG program, induction chemotherapy was integrated with early mediastinal irradiation in patients with suboptimal tumor regression, whereas the molecular analysis of MRD was used for the first time in adult LL to decide between SCT and standard maintenance for postinduction therapy.…”

Section: Discussionmentioning

confidence: 92%

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma

et al. 2011

View full text Add to dashboard Cite

The therapeutic role of mediastinal radiotherapy and stem cell transplantation (SCT) in lymphoblastic lymphoma (LL) remains controversial. In a risk-oriented design, we adopted a flexible treatment program in which (1) patients with persistent mediastinal abnormality, evaluated by post-induction computed chest tomography, received mediastinal irradiation; and (2) those with persistence of minimal residual disease (MRD), evaluated by MRD analysis of the bone marrow, underwent SCT.Twenty-eight out of 30 patients (T-lineage, n=24; Blineage, n=6) achieved a complete response. Of 21 patients with mediastinal mass, 13 (62%) achieved a complete response after chemotherapy alone, while 6 (28.5%) required additional irradiation. Eleven patients were evaluated for MRD: 6 were negative and 5 positive. On the basis of MRD findings and clinical risk characteristics, 14 patients underwent SCT, 13 received maintenance chemotherapy, and 1 had local radiotherapy. Five patients Sergio Cortelazzo and Renato Bassan contributed equally to the manuscript.Electronic supplementary material The online version of this article

show abstract

“…Previous studies compared MRD results obtained by FC and PCR in ALL, mostly in B-lineage [44][45][46][47][48]; some of them included very few patients [2][3][4][5][6][7][8][9][10][11][12][13][14][15] with T-cell ALL [44][45][46][47]. In our study of T-LLy involving BM at presentation, the positive/negative concordance between the two methods using a threshold of !0.01% was 67%.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast to ALL, very few prognostic factors have been identified in T-LLy, such as disease stage III versus IV [11,[13][14][15] and early response to treatment, as measured by resolution of the mediastinal mass [11,16,17], and their significance is controversial, depending on the therapy delivered. Early treatment response, expressed by levels of minimal residual disease (MRD) in bone marrow (BM)/peripheral blood (PBL), has proven to be a powerful predictor of treatment outcome [18][19][20][21][22][23][24] and was introduced to recent ALL treatment protocols for risk-group stratification [24,25].…”

Section: Introductionmentioning

confidence: 99%

Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T‐cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real‐time quantitative polymerase chain reaction (RQ‐PCR)

Stark

Avigad

Luria

et al. 2008

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundDespite overlapping features of T‐cell lymphoblastic lymphoma (T‐LLy) and T‐cell acute lymphoblastic leukemia (T‐ALL), which respond favorably to T‐ALL treatment, clinical and biological differences exist. We retrospectively assessed the prevalence of submicroscopic bone marrow (BM) minimal disseminated disease (MDD) at diagnosis and the early response to treatment (minimal residual disease—MRD) and their prognostic significance in 17 children with stage III T‐LLy treated according to Berlin‐Frankfurt‐Munster (BFM) non‐Hodgkin lymphoma protocols.ProcedureFour‐color flow cytometry (FC) was used for lymphoma associated immunophenotype and real‐time quantitative polymerase chain reaction (RQ‐PCR) for T‐cell receptor (TCR β/δ/γ) gene rearrangements with at least 0.01% sensitivity.ResultsTwo markers per patient were identified in all cases using FC and in 80% using RQ‐PCR. BM MDD at diagnosis of ≥0.01% was detected by FC and RQ‐PCR in 88% and 80% of patients, respectively, and by at least one of the methods in all patients. A significant correlation was achieved between the methods by Pearson correlation analysis (P = 0.004). MRD levels significantly decreased to very low levels on day 33 in 9 out of 10 patients studied. The only patient that remained positive relapsed.ConclusionsMDD was prevalent in stage III T‐LLy, for which we could not prove a prognostic significance in the context of ALL‐like treatment. This study shows that both FC and RQ‐PCR methods are efficient for MDD and MRD analyses in T‐LLy. Pediatr Blood Cancer 2009;52:20–25. © 2008 Wiley‐Liss, Inc.

show abstract

High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)

Cited by 37 publications

References 21 publications

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma

Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T‐cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real‐time quantitative polymerase chain reaction (RQ‐PCR)

Contact Info

Product

Resources

About